Rapport Therapeutics, Inc. Common Stock
NASDAQ:RAPPBiotechnology
+$0.02 today
- Market cap
- $1.12B
- Beta
- 0.98
- P/E (TTM)
- -16.2
- EPS (TTM)
- -$2.27
Volume 0.73M
Average 0.33M
RAPP Total Current Assets
All assets expected to be converted to cash or used up within one year.
Rapport Therapeutics, Inc. Common StockNASDAQ: RAPP
Total Current Assets · Q1 FY2026 · quarter ended Mar 2026
Total current assets rises 66.6% from a year ago
Total current assets stood at $484.7M at the end of Q1 FY2026, up 66.6% from a year earlier and down 2.8% from the prior quarter. Over 3 fiscal years it compounded at +151.7% a year.
Context
- Total current assets amounted to 97.4% of total assets at the end of Q1 FY2026, up 1.1 pp from a year earlier.
- Total current assets increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total current assets keeps rising in the next quarterly balance sheet after a +66.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Assets history
USD · from the balance sheet
- Latest · FY2025
- 498.56M USD
- Year-over-year change
- +60.9%
- 3-year CAGR
- +151.7%
| Period | Period end | Total Current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 498.56M | +60.9% |
| FY2024 | 2024-12-31 | 309.8M | +105.3% |
| FY2023 | 2023-12-31 | 150.87M | +382.5% |
| FY2022 | 2022-12-31 | 31.27M | — |
Total Current Assets vs competitors
How RAPP compares with its peers on the latest reported figures
- RAPP's Mar 2026 total current assets of $484.7M is the 4th highest of the 10 companies compared; the peer median is $327.23M.
- Its year-over-year change of +66.6% is the 4th highest of 10, against a peer median of +56.6%.
- Total current assets amounts to 97.4% of total assets for RAPP, versus a peer median of 96.8%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $1.27B | +17.8% | +27.9% | 70.7% | |
| Sep 2026 | $762.8M | +178.6% | +76.6% | 58.1% | |
| Jun 2026 | $656.57M | +22.4% | +33.8% | 86.2% | |
RAPPRapport Therapeutics, Inc. Common Stock | Mar 2026 | $484.7M | +66.6% | +151.7% | 97.4% |
LBRXLB Pharmaceuticals Inc Common Stock | Mar 2026 | $389.07M | +2532.3% | +143.0% | 98.9% |
| Mar 2026 | $327.23M | +233.0% | +116.4% | 78.1% | |
| Mar 2026 | $269.13M | +64.6% | +53.4% | 97.4% | |
CTNMContineum Therapeutics, Inc. Class A Common Stock | Mar 2026 | $252.96M | +31.7% | +76.9% | 96.8% |
NMRANeumora Therapeutics, Inc. Common Stock | Mar 2026 | $153.43M | -39.8% | -21.1% | 99.7% |
| Mar 2026 | $35.81M | +56.6% | +0.2% | 99.1% | |
SPTXSeaport Therapeutics, Inc. Common Stock | — | — | — | — | — |
| Peer median (excluding RAPP) | $327.23M | +56.6% | +53.4% | 96.8% | |
Competitors are the stored peer set for RAPP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Rapport Therapeutics, Inc. Common Stock
NASDAQ:RAPP
Intrinsic Alpha fair value
Locked
Current Price
$23.40
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.